Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Print
Riadh Lobbardi, PhD (he/him/his)
Director, Translational Medicine
C4 Therapeutics
Poster(s):
(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS